A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia

Trial Profile

A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2017

At a glance

  • Drugs NVK-002 (Primary)
  • Indications Myopia
  • Focus Registrational; Therapeutic Use
  • Acronyms CHAMP
  • Sponsors Nevakar
  • Most Recent Events

    • 30 Nov 2017 New trial record
    • 21 Nov 2017 Planned number of patients changed to 500, according to a Nevakar media release.
    • 21 Nov 2017 According to a Nevakar media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top